BioXcel Therapeutics, Inc. (BTAI) Free cash flow 2018–2025
BioXcel Therapeutics, Inc. (BTAI) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$57.6MFY2025 · since FY2018: -$13.8M → -$57.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$57.6M | +20.0% |
| FY2024 | -$72.0M | +53.5% |
| FY2023 | -$155.0M | -14.4% |
| FY2022 | -$135.5M | -64.0% |
| FY2021 | -$82.6M | -23.9% |
| FY2020 | -$66.7M | -138.3% |
| FY2019 | -$28.0M | -102.0% |
| FY2018 | -$13.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice